Acneiform Eruptions Julianne H
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chloracne: from Clinic to Research
DERMATOLOGICA SINICA 30 (2012) 2e6 Contents lists available at SciVerse ScienceDirect Dermatologica Sinica journal homepage: http://www.derm-sinica.com REVIEW ARTICLE Chloracne: From clinic to research Qiang Ju 1, Kuochia Yang 2, Christos C. Zouboulis 3, Johannes Ring 4, Wenchieh Chen 4,* 1 Department of Dermatology, Shanghai Skin Disease and STD Hospital, Shanghai, People’s Republic of China 2 Department of Dermatology, Changhua Christian Hospital, Changhua, Taiwan 3 Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany 4 Department of Dermatology and Allergy, Technische Universität München, Munich, Germany article info abstract Article history: Chloracne is the most sensitive and specific marker for a possible dioxin (2,3,7,8-tetrachlorodibenzo-p- Received: Oct 31, 2011 dioxin) intoxication. It is clinically characterized by multiple acneiform comedone-like cystic eruptions Revised: Nov 9, 2011 mainly involving face in the malar, temporal, mandibular, auricular/retroauricular regions, and the Accepted: Nov 9, 2011 genitalia, often occurring in age groups not typical for acne vulgaris. Histopathology is essential for adefinite diagnosis, which exhibits atrophy or absence of sebaceous glands as well as infundibular Keywords: dilatation or cystic formation of hair follicles, hyperplasia of epidermis, and hyperpigmentation of aryl hydrocarbon receptor stratum corneum. The appearance of chloracne and its clinical severity does not correlate with the blood chloracne “ ” 2,3,7,8-tetrachlorodibenzo-p-dioxin levels of dioxins. Pathogenesis of chloracne remains largely unclear. An aryl hydrocarbon receptor - polyhalogenated aromatic hydrocarbons mediated signaling pathway affecting the multipotent stem cells in the pilosebaceous units is probably sebaceous gland the major molecular mechanism inducing chloracne. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities. -
Cutaneous Adverse Effects of Biologic Medications
REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions -
Two Cases of Nevoid Basal Cell Carcinoma Syndrome in One Family
221 Two Cases of Nevoid Basal Cell Carcinoma Syndrome in One Family Dong Jin Ryu, M.D., Yeon Sook Kwon, M.D., Mi Ryung Roh, M.D., Min-Geol Lee, M.D., Ph.D. Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea The nevoid basal cell carcinoma syndrome, or Gorlin-Goltz syndrome, is an autosomal dominant multiple system disorder with high penetrance and variable expressions, although it can also arise spontaneously. The diagnostic criteria for nevoid basal cell carcinoma syndrome include multiple basal cell carcinomas, palmoplantar pits, multiple odontogenic keratocysts, skeletal anomalies, positive family history, ectopic calcification and neurological anomalies. We report a brother and sister who were both diagnosed with nevoid basal cell carcinoma syndrome. (Ann Dermatol (Seoul) 20(4) 221∼225, 2008) Key Words: Basal cell carcinoma, Nevoid basal cell carcinoma syndrome, Odontogenic keratocyst INTRODUCTION cell carcinoma syndrome. The nevoid basal cell carcinoma syndrome (NBCCS), or Gorlin-Goltz syndrome, is an auto- CASE REPORT somal dominant multiple system disorder with high 1 penetrance and variable expressions . However, Case 1 60% of patients with NBCCS are sporadic cases. It An 11-year-old male was referred to our depart- has an estimated prevalence of 1 in 60,000 with ment for the evaluation of multiple miliary sized 2 equal distributions among males and females . The pigmented macules on the palm and sole that had well-defined diagnostic criteria include cutaneous increased in number over several years. He had an anomalies, dento-facial anomalies, skeletal ano- operation for inguinal hernia at 3 years of age, but malies, positive family history, neurological ano- no other medical problems. -
Compensation for Occupational Skin Diseases
ORIGINAL ARTICLE http://dx.doi.org/10.3346/jkms.2014.29.S.S52 • J Korean Med Sci 2014; 29: S52-58 Compensation for Occupational Skin Diseases Han-Soo Song1 and Hyun-chul Ryou2 The Korean list of occupational skin diseases was amended in July 2013. The past list was constructed according to the causative agent and the target organ, and the items of that 1 Department of Occupational and Environmental list had not been reviewed for a long period. The revised list was reconstructed to include Medicine, College of Medicine, Chosun University, Gwangju; 2Teo Center of Occupational and diseases classified by the International Classification of Diseases (10th version). Therefore, Environmental Medicine, Changwon, Korea the items of compensable occupational skin diseases in the amended list in Korea comprise contact dermatitis; chemical burns; Stevens-Johnson syndrome; tar-related skin diseases; Received: 19 December 2013 infectious skin diseases; skin injury-induced cellulitis; and skin conditions resulting from Accepted: 2 May 2014 physical factors such as heat, cold, sun exposure, and ionized radiation. This list will be Address for Correspondence: more practical and convenient for physicians and workers because it follows a disease- Han-Soo Song, MD based approach. The revised list is in accordance with the International Labor Organization Department of Occupational and Environmental Medicine, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, list and is refined according to Korean worker’s compensation and the actual occurrence of Gwangju 501-717, Korea occupational skin diseases. However, this revised list does not perfectly reflect the actual Tel: +82.62-220-3689, Fax: +82.62-443-5035 E-mail: [email protected] status of skin diseases because of the few cases of occupational skin diseases, incomplete statistics of skin diseases, and insufficient scientific evidence. -
General Dermatology an Atlas of Diagnosis and Management 2007
An Atlas of Diagnosis and Management GENERAL DERMATOLOGY John SC English, FRCP Department of Dermatology Queen's Medical Centre Nottingham University Hospitals NHS Trust Nottingham, UK CLINICAL PUBLISHING OXFORD Clinical Publishing An imprint of Atlas Medical Publishing Ltd Oxford Centre for Innovation Mill Street, Oxford OX2 0JX, UK tel: +44 1865 811116 fax: +44 1865 251550 email: [email protected] web: www.clinicalpublishing.co.uk Distributed in USA and Canada by: Clinical Publishing 30 Amberwood Parkway Ashland OH 44805 USA tel: 800-247-6553 (toll free within US and Canada) fax: 419-281-6883 email: [email protected] Distributed in UK and Rest of World by: Marston Book Services Ltd PO Box 269 Abingdon Oxon OX14 4YN UK tel: +44 1235 465500 fax: +44 1235 465555 email: [email protected] © Atlas Medical Publishing Ltd 2007 First published 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Clinical Publishing or Atlas Medical Publishing Ltd. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. A catalogue record of this book is available from the British Library ISBN-13 978 1 904392 76 7 Electronic ISBN 978 1 84692 568 9 The publisher makes no representation, express or implied, that the dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. -
Acquired Bilateral Nevus of Ota–Like Macules (Hori's Nevus): a Case
Acquired Bilateral Nevus of Ota–like Macules (Hori’s Nevus): A Case Report and Treatment Update Jamie Hale, DO,* David Dorton, DO,** Kaisa van der Kooi, MD*** *Dermatology Resident, 2nd year, Largo Medical Center/NSUCOM, Largo, FL **Dermatologist, Teaching Faculty, Largo Medical Center/NSUCOM, Largo, FL ***Dermatopathologist, Teaching Faculty, Largo Medical Center/NSUCOM, Largo, FL Abstract This is a case of a 71-year-old African American female who presented with bilateral periorbital hyperpigmentation. After failing treatment with a topical retinoid and hydroquinone, a biopsy was performed and was consistent with acquired bilateral nevus of Ota-like macules, or Hori’s nevus. A review of histopathology, etiology, and treatment is discussed below. cream and tretinoin 0.05% gel. At this visit, a Introduction Figure 2 Acquired nevus of Ota-like macules (ABNOM), punch biopsy of her left zygoma was performed. or Hori’s nevus, clinically presents as bilateral, Histopathology reported sparse proliferation blue-gray to gray-brown macules of the zygomatic of irregularly shaped, haphazardly arranged melanocytes extending from the superficial area. It less often presents on the forehead, upper reticular dermis to mid-deep reticular dermis outer eyelids, and nose.1 It is most common in women of Asian descent and has been reported Figure 4 in ages 20 to 70. Classically, the eye and oral mucosa are uninvolved. This condition is commonly misdiagnosed as melasma.1 The etiology of this condition is not fully understood, and therefore no standardized treatment has been Figure 3 established. Case Report A 71-year-old African American female initially presented with a two week history of a pruritic, flaky rash with discoloration of her face. -
Herb Lotions to Regrow Hair in Patients with Intractable Alopecia Areata Hideo Nakayama*, Ko-Ron Chen Meguro Chen Dermatology Clinic, Tokyo, Japan
Clinical and Medical Investigations Research Article ISSN: 2398-5763 Herb lotions to regrow hair in patients with intractable alopecia areata Hideo Nakayama*, Ko-Ron Chen Meguro Chen Dermatology Clinic, Tokyo, Japan Abstract The history of herbal medicine in China goes back more than 1,000 years. Many kinds of mixtures of herbs that are effective to diseases or symptoms have been transmitted from the middle ages to today under names such as Traditional Chinese Medicine (TCM) in China and Kampo in Japan. For the treatment of severe and intractable alopecia areata, such as alopecia universalis, totalis, diffusa etc., herb lotions are known to be effective in hair regrowth. Laiso®, Fukisin® in Japan and 101® in China are such effective examples. As to treat such cases, systemic usage of corticosteroid hormones are surely effective, however, considering their side effects, long term usage should be refrained. There are also these who should refrain such as small children, and patients with peptic ulcers, chronic infections and osteoporosis. AL-8 and AL-4 were the prescriptions removing herbs which are not allowed in Japanese Pharmacological regulations from 101, and salvia miltiorrhiza radix (SMR) is the most effective herb for hair growth, also the causation to produce contact sensitization. Therefore, the mechanism of hair growth of these herb lotions in which the rate of effectiveness was in average 64.8% on 54 severe intractable cases of alopecia areata, was very similar to DNCB and SADBE. The most recommended way of developing herb lotion with high ability of hairgrowth is to use SMR but its concentration should not exceed 2%, and when sensitization occurs, the lotion should be changed to Laiso® or Fukisin®, which do not contain SMR. -
Co-Occurrence of Vitiligo and Becker's Nevus: a Case Report
Case Report Olgu Sunumu DOI: 10.4274/turkderm.71354 Turkderm - Arch Turk Dermatol Venerology 2016;50 Co-occurrence of vitiligo and Becker's nevus: A case report Vitiligo ve Becker nevüs birlikteliği: Olgu sunumu Ayşegül Yalçınkaya İyidal, Özge Çokbankir*, Arzu Kılıç** Ağrı State Hospital, Clinic of Dermatology, *Clinic of Pathology, Ağrı, Turkey **Balıkesir University Faculty of Medicine, Department of Dermatology, Balıkesir, Turkey Abstract Vitiligo is an acquired disorder with an unknown etiology in which genetic and non-genetic factors coexist. Melanocytes are destructed in the affected skin areas and clinically depigmented macules and patches appear on the skin. Becker's nevus (BN) appears as hyperpigmented macule, patch or verrucous plaques with sharp and irregular margins and often unilateral occurrence and with associated hypertrichosis in various degrees. Although its pathogenesis is unknown, it is suggested to represent a hamartomatous lesion harboring androgen receptors on the lesion. In this report, we present a 19-year-old male patient who developed vitiligo lesions and then BN adjacent to the vitiligo lesion in the right upper back portion of the body ten years after the initial vitiligo lesion. Keywords: Becker's nevus, vitiligo, co-occurrence Öz Vitiligo nedeni tam olarak bilinmeyen, genetik ve genetik olmayan faktörlerin birlikte rol oynadığı edinsel bir bozukluktur. Bu hastalıkta tutulan deride melanositler ortadan kalkar, klinik olarak depigmente makül ve yamalar belirir. Becker nevüs (BN) sıklıkla unilateral dağılım gösteren, keskin ama düzensiz sınırlı hiperpigmente makül, yama veya verrüköz plakların izlendiği, üzerinde değişik derecelerde hipertrikozun bulunduğu bir hastalıktır. Patogenezi belli olmamakla birlikte hamartamatöz bir lezyon olduğu ve üzerinde androjen reseptörlerinin arttığı ileri sürülmektedir. -
Acne in Childhood: an Update Wendy Kim, DO; and Anthony J
FEATURE Acne in Childhood: An Update Wendy Kim, DO; and Anthony J. Mancini, MD cne is the most common chron- ic skin disease affecting chil- A dren and adolescents, with an 85% prevalence rate among those aged 12 to 24 years.1 However, recent data suggest a younger age of onset is com- mon and that teenagers only comprise 36.5% of patients with acne.2,3 This ar- ticle provides an overview of acne, its pathophysiology, and contemporary classification; reviews treatment op- tions; and reviews recently published algorithms for treating acne of differing levels of severity. Acne can be classified based on le- sion type (morphology) and the age All images courtesy of Anthony J. Mancini, MD. group affected.4 The contemporary Figure 1. Comedonal acne. This patient has numerous closed comedones (ie, “whiteheads”). classification of acne based on sev- eral recent reviews is addressed below. Acne lesions (see Table 1, page 419) can be divided into noninflammatory lesions (open and closed comedones, see Figure 1) and inflammatory lesions (papules, pustules, and nodules, see Figure 2). The comedone begins with Wendy Kim, DO, is Assistant Professor of In- ternal Medicine and Pediatrics, Division of Der- matology, Loyola University Medical Center, Chicago. Anthony J. Mancini, MD, is Professor of Pediatrics and Dermatology, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital of Chi- cago. Address correspondence to: Anthony J. Man- Figure 2. Moderate mixed acne. In this patient, a combination of closed comedones, inflammatory pap- ules, and pustules can be seen. cini, MD, Division of Dermatology Box #107, Ann and Robert H. -
Dermoscopy on Nevus Comedonicus: a Case Report and Review of the Literature
Case report Dermoscopy on nevus comedonicus: a case report and review of the literature Grażyna Kamińska-Winciorek 1, Radosław Śpiewak 2 1The Center for Cancer Prevention and Treatment, Katowice, Poland Head: Beata Wydmańska 2Department of Experimental Dermatology and Cosmetology, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland Head: Prof. Radosław Śpiewak MD. PhD Postep Derm Alergol 2013; XXX, 4: 252 –254 DOI: 10.5114/pdia.2013.37036 Abstract Nevus comedonicus (NC) is a very rare, benign hamartoma characterised by the occurrence of dilated, comedo-like openings, typically on the face, neck, upper arms, chest or abdomen. In uncertain cases, histopathological exami - nation confirms the diagnosis. The authors suggest dermoscopy as a rapid and useful method of initial diagnosis of nevus comedonicus based upon its distinctive dermoscopic features. The dermoscopy reveals numerous light- and dark-brown, circular or barrel-shaped, homogenous areas with prominent keratin plugs. Key words: dermoscopy, dermatoscopy, nevus comedonicus, epidermal nevus, acne vulgaris. Introduction a hypopigmented, slightly hypotrophic, linear spot of Nevus comedonicus (NC) is a benign hamartoma cha - 2 cm × 8 cm (Figure 1). The plugs could not be extracted racterised by the occurrence of dilated comedo-like open - mechanically. The dermoscopic examination revealed ings, with black or brown keratin plugs, typically localised the distinctive pattern consisting of dark, sharply demar - on the face, neck, upper arms, chest or abdomen. The diag - cated keratin plugs of 1–3 mm diameter, numerous struc - nosis of nevus comedonicus is relatively easy. In uncertain tureless, circular- and barrel-shaped, homogenous areas cases, a typical histopathological picture confirms the diag - with hyperkeratotic plugs of various shades of brown nosis. -
Jemds.Com Original Research Article
Jemds.com Original Research Article DERMATOLOGICAL ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS: EXPERIENCE FROM A TERTIARY CENTRE Parvaiz Anwar Rather1, M. Hussain Mir2, Sandeep Kaul3, Vikas Roshan4, Jilu Mathews5, Bandu Sharma6 1Lecturer, Department of Dermatology, GMC, Jammu, Jammu & Kashmir, India. 2Consultant, Department of Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 3Consultant, Department of Surgical Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 4Consultant, Department of Radiation Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 5Senior Nursing In Charge, Department of Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 6Senior Nursing In Charge, Department of Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. ABSTRACT BACKGROUND Chemotherapeutic agents, both conventional and new targeted therapy, are known to cause diverse side effects related to skin, hair, mucous membranes and nails, collectively called `dermatological adverse effects`. But such association in literature is mostly confined to case reports/case series and small number of published papers. The aim of this study is to look for dermatological adverse effects and the most common culprit agents, with the objective that the oncologist and dermatologist team remain vigilant and adopt rational management protocol in their management to circumvent the morbidity and long-term toxicity as it involves the cosmetic appearance of long-term cancer survivor. MATERIALS AND METHODS This prospective hospital-based descriptive study was conducted jointly by the dermatologist and oncology team over a period of more than one year in a specialised tertiary centre on oncology patients, who developed dermatological side effects after initiation of anti-cancer drugs. RESULTS Out of 125 patients studied, dermatological adverse effects of varying duration were noticed in 27 patients (21.6%), with overall 45 side effects manifestation.